Add-On Treatment with Pregabalin for Patients with Uncontrolled Neuropathic Pain Who Have Been Referred to Pain Clinics

OBJECTIVE: The aim of this study was to investigate the impact of pregabalin on pain, other symptoms, and patient-reported outcomes for patients with uncontrolled pain who have been referred to pain clinics. PATIENTS AND METHODS: Adult patients with uncontrolled pain who had a score of ≥4 in the DN4 questionnaire were evaluated at baseline, month 3, and month 6. Evaluations included pain levels using a visual analog (VAS) scale as well as anxiety, depression, sleep, disability, and treatment satisfaction employing validated tools. RESULTS: Our sample comprised 413 patients who met the selection criteria, had not received pregabalin previously, and were prescribed pregabalin at the study initiation, mainly (97 %) as add-on therapy. Overall, patients had a statistically significant reduction in VAS pain score of 41 points (54 % reduction, p < 0.001), varying from 64 % reduction (oncological pain) to 31 % reduction (central neuropathic pain). Effect sizes for anxiety, depression, sleep, and treatment satisfaction improvement were moderate to large depending on the dimension and clinical entity. CONCLUSION: Our results suggest that in patients with uncontrolled neuropathic pain of various origins who were treated at pain clinics, the addition of pregabalin to a wider pharmacological treatment regimen was associated with a clinically relevant improvement of pain and psychological well-being and a reduction in the impact of neuropathic pain on daily activities. Add-on treatment with pregabalin was well tolerated.